6. (ABUS): Long-Term Hold With Advancements Into Several Areas Of Interest

Mar. 07, 2022 -

Summary

• Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.
• Results from the phase 1a/1b study using AB-729 for Hep B from multiple cohorts are expected at a medical conference in 2022.
• Results from the phase 1 study using AB-836 for the treatment of patients with Hepatitis B are expected in the 1st half of 2022.
• Patent litigation against Moderna for patent infringement dealing with its Covid-19 vaccine may possibly bring in revenue for Arbutus/Genevant should a deal be reached or successful litigation in court.

Summary

1. B형 간염에 대한 AB-729
1) 2022년 상반기: 2상 데이터를 기대하는 중.
2) 1a/1b상 study 결과는 2022년 의학 컨퍼런스에서 기대됨.

2. B형 간염에 대한 AB-836
- 2022년 상반기: 1상 데이터를 기대하는 중.

3. MRNA에 대한 Patent litigation
- patent infringement: should a deal be reached or successful litigation in court. => 합의 또는 법원 승소 필요.